June 27, 2024 - 🧬 [nGram] Today’s Oncology Scoop: EPKINLY® FDA Approval, GenVivo Trial, Cancer Drug Shortage

  1. Patritumab deruxtecan BLA submission receives complete response letter from FDA due to inspection findings at third-party manufacturer
    • The FDA issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) of patritumab deruxtecan for EGFR-mutated NSCLC.
    • The CRL was due to inspection findings at a third-party manufacturing facility, not related to the drug's efficacy or safety.
    • Patritumab deruxtecan is a HER3 directed DXd antibody drug conjugate developed by Daiichi Sankyo and Merck.
    • The BLA was based on results from the HERTHENA-Lung01 phase 2 trial, showing an objective response rate (ORR) of 29.8%.
    • The trial included 225 patients with EGFR-mutated NSCLC, showing a median duration of response of 6.4 months.
    • Next steps involve working closely with the FDA and the third-party manufacturer to address the feedback.
    Read more

  2. EPKINLY (epcoritamab-bysp) approved by U.S. FDA for patients with relapsed or refractory follicular lymphoma
    • The U.S. FDA has approved EPKINLY (epcoritamab-bysp) for adults with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy.
    • Approval is based on results from the Phase 1/2 EPCORE NHL-1 study, which showed an overall response rate (ORR) of 82% and a complete response (CR) rate of 60%.
    • EPKINLY is the first and only T-cell engaging bispecific antibody administered subcutaneously approved in the U.S. for this patient population.
    • Common treatment-emergent adverse events (TEAEs) included injection site reaction, cytokine release syndrome (CRS), COVID-19, fatigue, and upper respiratory tract infection.
    • The National Comprehensive Cancer Network (NCCN) has updated its guidelines to include EPKINLY as a Category 2A, preferred recommendation for third-line and subsequent therapy for patients with FL.
    • Continued approval may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial(s).
    Read more

  3. U.S. FDA grants second approval for epkinly to treat patients with relapsed or refractory follicular lymphoma
    • EPKINLY is the first and only bispecific antibody approved in the U.S. for both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL).
    • The approval is under the FDA's Accelerated Approval program based on overall response rate (ORR) and durability of response.
    • The Phase 1/2 EPCORE NHL-1 clinical trial showed an ORR of 82%, with a complete response rate of 60% and a partial response rate of 22%.
    • Safety was evaluated in 213 patients, with common adverse reactions including injection site reactions, cytokine release syndrome (CRS), and fatigue.
    • EPKINLY is co-developed by AbbVie and Genmab, with shared commercial responsibilities in the U.S. and Japan.
    • AbbVie will continue to pursue regulatory submissions for epcoritamab across international markets.
    Read more

  4. University of Nebraska Medical Center launches patient enrollment for RenovoRx’s pivotal phase III TIGeR-PaC clinical trial
    • University of Nebraska Medical Center (UNMC) is enrolling patients with locally advanced pancreatic cancer (LAPC) in RenovoRx’s Phase III TIGeR-PaC clinical trial.
    • The trial uses RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform to evaluate the RenovoGem drug-device combination.
    • RenovoGem delivers chemotherapy directly to tumor tissue, aiming to improve drug penetration and effectiveness.
    • The study compares TAMP therapy to the current standard-of-care, systemic intravenous chemotherapy.
    • The primary endpoint is a 6-month overall survival benefit, with secondary endpoints including reduced side effects.
    • The second interim analysis will be triggered by the 52nd event, estimated to occur in late 2024.
    Read more

  5. GenVivo announces initiation of patient dosing in a US Phase I/Ib clinical trial evaluating GEN2 in patients with advanced solid tumors
    • GenVivo has started dosing the first US patient in a Phase I/Ib clinical trial for GEN2.
    • The trial, GVO-1102, aims to establish the Recommended Phase 2 Dose (RP2D) and will expand into three solid tumor types.
    • GEN2 is a non-replicating mRNA gene therapy vector designed to kill tumors and activate the patient's immune system.
    • The trial will assess safety, tolerability, pharmacokinetics, and exploratory biomarkers.
    • GEN2 offers the benefits of personalized therapy without the delays and costs of autologous products or tumor genome sequencing.
    • The trial is currently enrolling US patients with advanced solid tumors who have not responded to prior therapies.
    Read more

  6. X4 Pharmaceuticals announces positive interim clinical data from ongoing six-month phase 2 trial of mavorixafor in chronic neutropenia and initiation of pivotal phase 3 CN trial
    • 100% of evaluable participants at Month 6 achieved target absolute neutrophil count (ANC) increase with once-daily, oral mavorixafor +/- stable-dose G-CSF.
    • Durable mean ANC levels above the lower limit of normal for CN were achieved for participants on mavorixafor monotherapy at Months 3 and 6.
    • The company is currently screening patients for enrollment into its global, pivotal Phase 3 clinical trial, the 4WARD study.
    • The 52-week Phase 3 trial is a randomized, double-blind, placebo-controlled, multicenter study aiming to enroll 150 participants.
    • Interim analysis showed mavorixafor was generally well tolerated and durably increased participants’ ANC both as a monotherapy and in combination with stable doses of G-CSF.
    • No drug-related serious adverse events were reported, and the overall safety profile remains consistent with previous clinical studies.
    Read more

  7. Resolution Therapeutics receives MHRA approval to commence Phase I/II EMERALD study for lead candidate RTX001
    • Resolution Therapeutics has received approval from the U.K. MHRA to start the Phase I/II EMERALD study for RTX001.
    • The EMERALD study will investigate the safety and efficacy of engineered macrophage cell therapy in patients with decompensated liver cirrhosis.
    • Primary analysis will focus on safety and major clinical events, including death, and will evaluate biomarkers like the MELD score.
    • The study is set to begin in Q3 2024.
    • The approval follows key proof of concept data presented at the EASL Congress 2024, demonstrating the effectiveness of non-engineered macrophage cell therapy for advanced liver cirrhosis.
    • Resolution Therapeutics will host an R&D Webinar on June 28, 2024, featuring hepatologist Arun Sanyal, M.D.
    Read more

  8. Clinical study showing ClarityDX Prostate accurately predicts a patient's risk of having clinically significant prostate cancer published in Nature Digital Medicine
    • Results of an international multi-center study evaluating ClarityDX Prostate's accuracy are now public.
    • The study, published in npj Digital Medicine, highlights the test's use of machine learning and blood-based biomarkers.
    • ClarityDX Prostate showed 95% sensitivity, 35% specificity, 54% positive predictive value, and 91% negative predictive value.
    • The test could potentially avoid up to 35% of unnecessary prostate biopsies.
    • ClarityDX Prostate was found to be three times more accurate than other risk calculators and PSA alone.
    • The study supports using ClarityDX Prostate as an adjunctive test for men with elevated PSA levels.
    Read more

  9. New survey from NCCN finds cancer drug shortage management remains a moving target, impacting clinical trials
    • NCCN's latest survey reveals ongoing cancer drug shortages in the US, with 89% of centers reporting shortages of at least one type of systemic therapy.
    • Specific shortages of carboplatin and cisplatin have decreased to 11% and 7% respectively, but new concerns have emerged.
    • 57% of surveyed centers reported a shortage of vinblastine, 46% for etoposide, and 43% for topotecan.
    • Drug shortages are affecting clinical trials at 43% of centers, impacting budgeting, enrollment, and increasing administrative burden.
    • 27% of centers reported treatment delays due to shortage-related changes requiring additional prior authorization.
    • NCCN advocates for sustainable, long-term solutions, including economic incentives for generic drugmakers to ensure a stable supply of high-quality cancer medications.
    Read more

  10. Fostrox + Lenvima holds promise of greatly improved outcomes for advanced liver cancer patients, reveals new data from Medivir at ESMO GI
    • Medivir presented new data from its Phase 1b/2a open-label trial of fostrox + Lenvima at the ESMO GI Congress.
    • The combination achieved a 24% overall response rate (ORR) and a median time to progression (TTP) of 10.8 months.
    • One patient remains on treatment after 22 months, showing a sustained partial response.
    • Biopsies confirmed selective DNA damage to tumor cells with no impact on normal liver function.
    • Only 5% of patients had to discontinue due to adverse events, indicating a favorable safety profile.
    • Medivir is finalizing the study protocol to open an IND in the US, expected in H2 2024.
    Read more